Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TMPRSS2 inhibitor

DRUG CLASS:

TMPRSS2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

AR positive	Breast Cancer	AR positive	Breast Cancer	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2
HR positive + AR positive	HER2 Negative Breast Cancer	HR positive + AR positive	HER2 Negative Breast Cancer	fulvestrant + GT0918 Sensitive: C3 – Early Trials fulvestrant + GT0918 Sensitive : C3	fulvestrant + GT0918 Sensitive: C3 – Early Trials fulvestrant + GT0918 Sensitive : C3
AR positive	Prostate Cancer	AR positive	Prostate Cancer	GT0918 Sensitive: D – Preclinical GT0918 Sensitive : D	GT0918 Sensitive: D – Preclinical GT0918 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + nafamostat Sensitive: D – Preclinical palbociclib + nafamostat Sensitive : D	palbociclib + nafamostat Sensitive: D – Preclinical palbociclib + nafamostat Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	nafamostat Sensitive: D – Preclinical nafamostat Sensitive : D	nafamostat Sensitive: D – Preclinical nafamostat Sensitive : D